Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 526

1.

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.

Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S.

Leuk Lymphoma. 2019 Jan 11:1-8. doi: 10.1080/10428194.2018.1543876. [Epub ahead of print]

PMID:
30632841
2.

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN.

Leukemia. 2018 Dec 21. doi: 10.1038/s41375-018-0334-3. [Epub ahead of print]

PMID:
30575820
3.

Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.

Swaminathan M, Patel KP, Huynh-Lu J, Tang G, Zuo Z, Miranda R, Verstovsek S.

Acta Haematol. 2019;141(1):23-27. doi: 10.1159/000494427. Epub 2018 Nov 21.

PMID:
30463063
4.

Utility of JAK2 V617F allelic burden in distinguishing chronic Myelomonocytic leukemia from primary myelofibrosis with Monocytosis.

Hu Z, Ramos CB, Medeiros LJ, Zhao C, Yin CC, Li S, Hu S, Wang W, Thakral B, Xu J, Verstovsek S, Lin P.

Hum Pathol. 2018 Nov 15. pii: S0046-8177(18)30423-4. doi: 10.1016/j.humpath.2018.10.026. [Epub ahead of print]

PMID:
30447300
5.

Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non Nocere.

Masarova L, Verstovsek S.

J Clin Oncol. 2018 Oct 22:JCO2018793497. doi: 10.1200/JCO.2018.79.3497. [Epub ahead of print]

PMID:
30346901
6.

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.

Couban S, Benevolo G, Donnellan W, Cultrera J, Koschmieder S, Verstovsek S, Hooper G, Hertig C, Tandon M, Dimier N, Malhi V, Passamonti F.

J Hematol Oncol. 2018 Sep 24;11(1):122. doi: 10.1186/s13045-018-0661-x.

7.

Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.

Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G.

Leuk Res. 2018 Oct;73:78-85. doi: 10.1016/j.leukres.2018.09.004. Epub 2018 Sep 14.

PMID:
30245189
8.

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.

Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S.

Blood. 2018 Nov 8;132(19):2100-2103. doi: 10.1182/blood-2018-05-848473. Epub 2018 Sep 21. No abstract available.

PMID:
30242087
9.

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N.

Blood. 2018 Oct 18;132(16):1664-1674. doi: 10.1182/blood-2018-04-846626. Epub 2018 Sep 5.

10.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H.

Lancet Haematol. 2018 Sep;5(9):e411-e421. doi: 10.1016/S2352-3026(18)30132-7. Epub 2018 Aug 13.

PMID:
30115541
11.

A multimodality work-up of patients with Hypereosinophilia.

Hu Z, Boddu PC, Loghavi S, Miranda RN, Goswami M, Medeiros LJ, Tam W, Orazi A, Verstovsek S, Wang SA.

Am J Hematol. 2018 Nov;93(11):1337-1346. doi: 10.1002/ajh.25247. Epub 2018 Sep 26.

PMID:
30105844
12.

Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis.

Verstovsek S, Yeleswaram S, Hou K, Chen X, Erickson-Viitanen S.

Hematol Oncol. 2018 Oct;36(4):701-708. doi: 10.1002/hon.2544. Epub 2018 Sep 11.

13.

Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.

Mughal TI, Lion T, Abdel-Wahab O, Mesa R, Scherber RM, Perrotti D, Mauro M, Verstovsek S, Saglio G, Van Etten RA, Kralovics R.

Hematol Oncol. 2018 Dec;36(5):740-748. doi: 10.1002/hon.2537. Epub 2018 Aug 3. Review.

PMID:
30074634
14.

Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis.

Veletic I, Manshouri T, Newberry KJ, Garnett J, Verstovsek S, Estrov Z.

Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15528. [Epub ahead of print] No abstract available.

PMID:
30074241
15.

Patient Perceptions in Mast Cell Disorders.

Jennings SV, Slee VM, Zack RM, Verstovsek S, George TI, Shi H, Lee P, Castells MC.

Immunol Allergy Clin North Am. 2018 Aug;38(3):505-525. doi: 10.1016/j.iac.2018.04.006. Review.

16.

Kit Mutations: New Insights and Diagnostic Value.

Falchi L, Verstovsek S.

Immunol Allergy Clin North Am. 2018 Aug;38(3):411-428. doi: 10.1016/j.iac.2018.04.005. Epub 2018 Jun 9. Review.

PMID:
30007460
17.

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.

Harrison CN, Griesshammer M, Miller C, Masszi T, Passamonti F, Zachee P, Durrant S, Pane F, Guglielmelli P, Verstovsek S, Jones MM, Hunter DS, Sun W, Li J, Khan M, Habr D, Kiladjian JJ.

Br J Haematol. 2018 Jul;182(2):279-284. doi: 10.1111/bjh.14764. Epub 2017 May 17. No abstract available.

PMID:
29984424
18.

Renal complications of primary myelofibrosis.

Strati P, Glass WF, Abdelrahim M, Selamet U, Tchakarov A, Workeneh BT, Verstovsek S, Abudayyeh A.

Leuk Lymphoma. 2018 Jul 3:1-4. doi: 10.1080/10428194.2018.1474525. [Epub ahead of print] No abstract available.

PMID:
29966471
19.

The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.

Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S.

Ann Hematol. 2018 Nov;97(11):2071-2080. doi: 10.1007/s00277-018-3402-x. Epub 2018 Jun 27.

PMID:
29951914
20.

Management of Myelofibrosis-Related Cytopenias.

Bose P, Verstovsek S.

Curr Hematol Malig Rep. 2018 Jun;13(3):164-172. doi: 10.1007/s11899-018-0447-9. Review.

PMID:
29796726
21.

Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.

Verstovsek S, Subbiah V, Masarova L, Yin CC, Tang G, Manshouri T, Asatiani E, Daver NG.

Ann Oncol. 2018 Aug 1;29(8):1880-1882. doi: 10.1093/annonc/mdy173. No abstract available.

PMID:
29767670
22.

Highlights in myeloproliferative neoplasms from the 2017 American Society of Hematology Annual Meeting: commentary.

Verstovsek S.

Clin Adv Hematol Oncol. 2018 Feb;16 Suppl 4(2):20-23. No abstract available.

PMID:
29742090
23.

MYC protein expression is an important prognostic factor in acute myeloid leukemia.

Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE.

Leuk Lymphoma. 2018 May 9:1-12. doi: 10.1080/10428194.2018.1464158. [Epub ahead of print]

PMID:
29741984
24.

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.

Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA.

Genome Res. 2018 Apr;28(4):432-447. doi: 10.1101/gr.225128.117. Epub 2018 Mar 22.

25.

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.

Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z.

Ann Hematol. 2018 Jul;97(7):1183-1191. doi: 10.1007/s00277-018-3289-6. Epub 2018 Mar 20.

PMID:
29557496
26.

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J.

Lancet Haematol. 2018 Apr;5(4):e136-e146. doi: 10.1016/S2352-3026(18)30021-8. Epub 2018 Mar 14.

PMID:
29550383
27.

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, Verstovsek S.

J Hematol Oncol. 2018 Mar 15;11(1):42. doi: 10.1186/s13045-018-0585-5.

28.

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.

Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S.

JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818.

29.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G.

Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Review.

PMID:
29515238
30.

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.

Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S.

Ann Hematol. 2018 Apr;97(4):617-627. doi: 10.1007/s00277-017-3225-1. Epub 2018 Feb 2.

PMID:
29396713
31.

Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure.

Alhuraiji A, Naqvi K, Huh YO, Ho C, Verstovsek S, Bose P.

Clin Case Rep. 2017 Dec 6;6(1):155-161. doi: 10.1002/ccr3.1264. eCollection 2018 Jan.

32.

Ruxolitinib for essential thrombocythemia?

Bose P, Verstovsek S.

Oncoscience. 2017 Nov 1;4(11-12):148-149. doi: 10.18632/oncoscience.373. eCollection 2017 Nov. No abstract available.

33.

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM.

Blood Adv. 2017 Jul 19;1(17):1312-1323. doi: 10.1182/bloodadvances.2017008227. eCollection 2017 Jul 25.

34.

Therapy-related myelofibrosis does not appear to exist.

Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S.

Blood Adv. 2017 May 26;1(14):863-866. doi: 10.1182/bloodadvances.2017007369. eCollection 2017 Jun 13.

35.

Bone marrow findings in blast phase of polycythemia vera.

Hidalgo López JE, Carballo-Zarate A, Verstovsek S, Wang SA, Hu S, Li S, Xu J, Zuo W, Tang Z, Yin CC, Medeiros LJ, Bueso-Ramos CE, Tang G.

Ann Hematol. 2018 Mar;97(3):425-434. doi: 10.1007/s00277-017-3211-7. Epub 2017 Dec 28.

PMID:
29285580
36.

SOHO State-of-the-Art Update and Next Questions: MPN.

Bose P, Gotlib J, Harrison CN, Verstovsek S.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):1-12. doi: 10.1016/j.clml.2017.11.008. Review.

37.

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.

Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S.

Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.

PMID:
29275119
38.

Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation.

Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat UR.

Br J Haematol. 2018 Dec;183(5):831-835. doi: 10.1111/bjh.15059. Epub 2017 Dec 19. No abstract available.

PMID:
29265180
39.

Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.

Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S.

Eur J Haematol. 2018 Mar;100(3):257-263. doi: 10.1111/ejh.13005. Epub 2018 Jan 17.

PMID:
29226426
40.

Targeting cistrome and dysregulated transcriptome of post-MPN sAML.

Verstovsek S, Fiskus W, Manshouri T, Bhalla KN.

Oncotarget. 2017 Oct 11;8(55):93301-93302. doi: 10.18632/oncotarget.21752. eCollection 2017 Nov 7. No abstract available.

41.

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S.

Exp Hematol Oncol. 2017 Nov 9;6:30. doi: 10.1186/s40164-017-0090-5. eCollection 2017.

42.

Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.

Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N.

Ann Hematol. 2018 Jan;97(1):109-121. doi: 10.1007/s00277-017-3165-9. Epub 2017 Nov 15.

PMID:
29143068
43.

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N.

Am J Hematol. 2018 Feb;93(2):277-285. doi: 10.1002/ajh.24972. Epub 2017 Nov 27.

PMID:
29134664
44.

Myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N.

Leuk Lymphoma. 2018 Jul;59(7):1672-1676. doi: 10.1080/10428194.2017.1397663. Epub 2017 Nov 9.

PMID:
29119847
45.

JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis.

Strati P, Benton CB, Manshouri T, Zhang Y, Bove JE 4th, Sanchez-Petitto G, Verstovsek S.

Leuk Res. 2017 Dec;63:53-55. doi: 10.1016/j.leukres.2017.10.016. Epub 2017 Oct 31.

PMID:
29101828
46.

Prognostication and Initiation of Therapy in Polycythemia Vera: Do We Have it Right?

Stein BL, Verstovsek S.

Curr Hematol Malig Rep. 2017 Dec;12(6):507-509. doi: 10.1007/s11899-017-0423-9. Review.

PMID:
29032412
47.

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.

Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J.

Am J Hematol. 2018 Jan;93(1):84-90. doi: 10.1002/ajh.24943. Epub 2017 Nov 9.

48.

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H.

J Natl Compr Canc Netw. 2017 Oct;15(10):1193-1207. doi: 10.6004/jnccn.2017.0157.

PMID:
28982745
49.

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.

Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J.

Leuk Lymphoma. 2018 Jun;59(6):1312-1322. doi: 10.1080/10428194.2017.1379076. Epub 2017 Oct 3.

PMID:
28972430
50.

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.

Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P, Dong T, Gopalakrishna P, Gupta V.

J Hematol Oncol. 2017 Sep 29;10(1):156. doi: 10.1186/s13045-017-0527-7.

Supplemental Content

Loading ...
Support Center